Trump administration sees FDA enforcement actions decline
Posted: 2 July 2019 | Victoria Rees (European Pharmaceutical Review) | No comments yet
A study has shown the warning letters the FDA distributes have decreased by a third since Trump came to office.
A recent study has shown that the US Food and Drug Administration (FDA) has had a significant decline in compliance and enforcement actions since Donald Trump became president of the US in 2016.
The investigation reports that agency warning letters have fallen by a third since 2016. Another finding of the investigation is that the warning letters declined between the first year of Trump’s office and his second, dispelling the possibility that a slow start to the president’s administration was to blame, says Charles Piller, who conducted the investigation.
The insights were revealed through an analysis of enforcement and compliance data from the agency’s public records. While the cause of the overall decline in FDA warnings is unclear, Piller notes that agency watchers and FDA insiders find the trend alarming.
A written statement by the FDA reported that “less discernible, but equally vital” regulatory and compliance actions are ongoing.
